A CRO, or contract research organization, is a company that pharmaceutical, biotech, and medical device firms hire to handle research and development work they don’t do in-house. CROs run clinical trials, test drug safety, manage enormous datasets, and navigate the regulatory process on behalf of their clients. The global CRO market is projected to reach $74.37 billion by 2026, reflecting how central these organizations have become to getting new treatments from the lab to the pharmacy shelf.
The acronym actually covers two overlapping types of organizations. Contract research organizations focus on preclinical work like toxicology testing, drug formulation, and lab analysis. Clinical research organizations specialize in managing clinical trials, the human-testing phase of drug development. Many large CROs do both, offering end-to-end support from early research through regulatory approval.
What CROs Actually Do
At the preclinical stage, CROs handle the foundational science that determines whether a drug candidate is worth testing in people. This includes toxicology studies to evaluate safety, stability testing to see how a drug holds up under different conditions, studies on how the body absorbs and breaks down a compound, and formulation development to figure out the best way to deliver it (pill, injection, patch, etc.). They also develop and validate the analytical methods used to measure drug purity and concentration in biological samples.
Once a drug moves into clinical trials, CROs take on a different set of responsibilities. They help design study protocols, recruit patients, select trial sites, and monitor the trial as it runs. They collect and manage the data generated during the trial, perform statistical analysis, and write the reports that get submitted to regulators. They also track adverse events and safety signals throughout the process, a function known as pharmacovigilance. Behind all of this sits a layer of project management and logistics, from shipping investigational drugs to coordinating teams across dozens of countries.
Why Companies Outsource to CROs
Running a clinical trial is expensive, complex, and requires specialized expertise that many companies, especially smaller biotech firms, simply don’t have. Clinical monitoring alone can represent 35% to 45% of a trial’s total cost, and CROs offer the infrastructure and experienced staff to manage that work more efficiently than building those capabilities from scratch.
Speed matters too. Drug development timelines are long, and delays cost money. CROs maintain networks of trial sites and investigators around the world, which helps sponsors launch trials faster and recruit patients more quickly. They also bring regulatory knowledge specific to different countries, which is critical for global trials that need to satisfy multiple regulatory agencies simultaneously.
There are two main ways companies structure these partnerships. In a full-service model, a single CRO handles trial delivery from start to finish, with integrated project management and one point of accountability. The trade-off is that the sponsor gives up some direct control. In a functional service provider (FSP) model, the sponsor outsources specific roles or functions while keeping tighter oversight. FSP staff often work within the sponsor’s own systems and processes, essentially acting as an extension of the in-house team. This gives the sponsor more flexibility but creates more coordination points between teams.
Regulatory Standards CROs Follow
CROs operate under strict regulatory frameworks, most notably the International Council for Harmonisation’s guidelines for Good Clinical Practice (ICH-GCP). These guidelines govern how trials are designed, conducted, recorded, and reported, with the overarching goal of protecting participants and ensuring data reliability.
One critical principle in these guidelines: the sponsor (the company that hired the CRO) always retains ultimate responsibility for the trial, even when they’ve outsourced every operational task. The sponsor must assess whether the CRO is suitable before hiring them, document exactly which responsibilities are being transferred, and maintain ongoing oversight of the work. CROs, in turn, are required to implement quality management systems and report any incidents that could affect participant safety or trial results. This creates a layered accountability structure where both parties share the obligation to protect patients and produce trustworthy data.
Data Management and Biostatistics
The data side of clinical trials is one of the most technically demanding areas CROs handle. Data management teams design the electronic forms used to capture patient information, review incoming clinical data for errors and trends, integrate data from outside sources like central labs, code medical events using standardized dictionaries, and deliver a clean, analyzable database that meets industry formatting standards.
Biostatisticians then take that data and do the analytical work that determines whether a treatment actually works. This includes designing the statistical analysis plan before the trial starts, generating randomization plans that assign patients to treatment or placebo groups, running the primary and secondary analyses, and supporting interim safety reviews by independent monitoring committees. They also perform the integrated efficacy and safety analyses that form the backbone of regulatory submissions. All of this analysis feeds into the clinical study reports and manuscripts that communicate trial results to regulators and the medical community.
Major CROs in the Industry
The industry spans hundreds of organizations, from global giants to niche specialists. IQVIA, one of the largest, operates in over 100 countries and has been conducting clinical trials since the early 1980s. ICON plc, founded in Dublin in 1990, employs nearly 42,000 people across 55 countries and has invested heavily in digital monitoring and data analytics. PPD, now part of Thermo Fisher Scientific, grew from a one-person consulting firm in 1985 into a worldwide operation covering everything from early study design to site selection.
Labcorp Drug Development brings over five decades of experience and maintains more than 186,000 clinical investigator sites globally. Parexel, with over 21,000 employees, covers the full range of phase 1 through phase 4 development. Smaller firms carve out niches too. Pharm-Olam specializes in rare and orphan diseases, infectious diseases, oncology, and autoimmune conditions. Medpace, based in Cincinnati, positions itself as a mid-sized CRO that maintains closer, more hands-on relationships with its partners.
How CROs Are Changing
The biggest shift in clinical research right now is the move toward decentralized trials, where participants can take part from home or local community centers instead of traveling to a dedicated research site. CROs are building the digital infrastructure to make this work, using platforms that allow remote consent, virtual visits, and electronic data capture outside traditional clinical settings.
Wearable devices are a key part of this shift. Trial participants can now wear sensors that continuously track heart rate, blood pressure, activity levels, sleep patterns, oxygen saturation, and blood glucose, all transmitted to researchers in real time. This eliminates gaps in data collection that occur when measurements are only taken during occasional clinic visits, and it reduces the burden on patients who would otherwise need to travel repeatedly. Artificial intelligence layered on top of this data can flag patterns or anomalies faster than manual review, predict health outcomes based on real-time trends, and tailor monitoring to individual patients. Real-time data collection also reduces the risk of data loss that comes with traditional, delayed methods of gathering trial information.